ClinicalTrials.gg
RecruitingNCT07661537Updated Aug 7, 2026

A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of SHR-3079 Injection in B-cell Non-Hodgkin Lymphoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
53rd of 273
90 · median 30
Started
2026
with 25 others
Phase 1
124 of 283
57 open now
Primary completion
2027-12
later than 99 of 145 live
Registered
278th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 53rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 26 that started in 2026, is one of 124 in phase 1, reaches primary completion later than 99 of the 145 other live ones, and was the 278th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.

03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old;
  2. (ECOG) performance status score of 0-1, expected survival ≥ 3 months;
  3. confirmed B-NHL;
  4. Participant population: Have received ≥ 1 line of standard anti-tumor treatment, and have not achieved response after the latest treatment or have progressive disease after the treatment;
  5. Have ;
  6. Have adequate organ function;
  7. Male participants and female participants of must use adequate and effective measures during the study and within 3 months after the last drug administration of SHR-3079. Female participants must not be lactating and must have a negative blood HCG test result within 7 days before the first dose;
  8. Voluntarily sign the ICF, have good compliance, and be willing to cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) infiltration;
  2. Prior chemotherapy or other anti-lymphoma agents administered within 4 weeks before the first dose of study treatment;
  3. Major surgery within 4 weeks before signing the ICF, or plan to undergo major surgery during the study period;
  4. Receipt of CAR-T therapy or stem cell transplant within 12 weeks prior to enrollment;
  5. Receipt of allogeneic hematopoietic stem cell transplantation;
  6. Prior solid organ transplantation;
  7. Positive virus (HCV) antibody with HCV-RNA copy number above the of the study site; positive surface antigen [HBsAg] and/or positive hepatitis B core antibody (HBcAb) with HBV DNA copy number above the upper limit of normal of the study site;
  8. Presence of severe disorders involving major organ systems;
  9. Pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention;
  10. Pregnant, lactating women, or women planning to become pregnant;
  11. Have other serious physical or mental illness, laboratory test abnormalities, or other factors that may increase the risk of study participation or interfere with the study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    SHR-3079 Group

    SHR-3079.

    Drug: SHR-3079 Injection

Interventions

  • DrugSHR-3079 Injection

    SHR-3079 injection.

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT)

    Time frame: 28 days after treatment initiation.

  2. Maximum tolerated dose (MTD)

    Time frame: Approximately 1 year.

  3. Recommended Phase II Dose (RP2D)

    Time frame: Approximately 1 year.

Secondary outcomes

  1. Types, incidence and severity of Adverse events (AEs)

    Safety endpoints.

    Time frame: Approximately 1 year.

  2. Serious adverse events (SAEs)

    Safety endpoints.

    Time frame: Approximately 1 year.

  3. Peak concentration (Cmax)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  4. Time to peak concentration (Tmax)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  5. Area under the curve (AUC0-t, AUC0-inf)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  6. Half-life (t1/2)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  7. Apparent clearance (CL/F)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  8. Apparent volume of distribution (Vz/F)

    Pharmacokinetics (PK) Parameters.

    Time frame: Approximately 1 year.

  9. Objective Response Rate (ORR)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

  10. Best Overall Efficacy(BOR)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

  11. Time to Response (TTR)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

  12. Duration of Response (DoR)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

  13. Progression-Free Survival (PFS)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

  14. Overall Survival (OS)

    Preliminary efficacy endpoints.

    Time frame: Approximately 1 year.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 17 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jul 23, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661537
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 23, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 7, 2026

Study contacts

Wei Ji, M.M
Contact
wei.ji.wj10@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion